{"DataElement":{"publicId":"2677021","version":"2","preferredName":"New Malignant Neoplasm Lymphoproliferative Disorder Myelodysplastic/Myeloproliferative Disease Diseases and Disorders Diagnosis Type","preferredDefinition":"A description of the new malignant neoplasm, lymphoproliferative or myelodysplastic / myeloproliferative disorder.","longName":"2587712v1.0:2676595v1.2","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2587712","version":"1","preferredName":"New Malignant Neoplasm Lymphoproliferative Disorder Myelodysplastic/Myeloproliferative Disease Diseases and Disorders Diagnosis","preferredDefinition":"information related to the diagnosis, investigation, analysis and recognition of the presence and nature of a new, distinct tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues, disease, disorder characterized by proliferation of lymphocytes at various stages of differentiation, or category of clonal myeloid disorders that have both myelodysplastic and chronic myeloproliferative features at the time of initial presentation.","longName":"N_MAL_LYM_MYE_DZ_DX","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2587710","version":"1","preferredName":"New Malignant Neoplasm Lymphoproliferative Disorder Myelodysplastic/Myeloproliferative Disease Diseases and Disorders","preferredDefinition":"New; having no previous example or precedent or parallel.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004:A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). --2004:A category of clonal myeloid disorders that have both myelodysplastic and chronic myeloproliferative features at the time of initial presentation.  (WHO, 2001) -- 2003:A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C25586:C9305:C9308:C27262:C299","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"New","conceptCode":"C25586","definition":"Having no previous example or precedent or parallel; of a kind not seen before.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Lymphoproliferative Disorder","conceptCode":"C9308","definition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myelodysplastic/Myeloproliferative Neoplasm","conceptCode":"C27262","definition":"A category of clonal hematopoietic disorders that have both myelodysplastic and myeloproliferative features at the time of initial presentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"272E80F5-85B1-6722-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-16","modifiedBy":"ONEDATA","dateModified":"2007-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2239981","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-1C71-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-26","modifiedBy":"ONEDATA","dateModified":"2005-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"272E80F5-85BF-6722-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-16","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-16","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2676595","version":"1.2","preferredName":"Malignant Neoplasm Type","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas. _Something distinguishable as an identifiable class based on common qualities.","longName":"2676595v1.2","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Post-transplant lymphoproliferative disorder (PTLD)","valueDescription":"Post-Transplant Lymphoproliferative Disorder","ValueMeaning":{"publicId":"3251848","version":"1","preferredName":"Post-Transplant Lymphoproliferative Disorder","longName":"3251848","preferredDefinition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft.  PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post-Transplant Lymphoproliferative Disorder","conceptCode":"C4727","definition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A771271A-FF2C-B6CD-E040-BB89AD436FA1","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292A1420-D69D-B90E-E050-BB89AD437CF4","beginDate":"2016-01-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Uncontrolled proliferation of donor cells without malignant transformation","valueDescription":"Uncontrolled Proliferation Tissue Donor Cell Without Malignant Transformation","ValueMeaning":{"publicId":"5100374","version":"1","preferredName":"Uncontrolled Proliferation Tissue Donor Cell Without Malignant Transformation","longName":"5100374","preferredDefinition":"Not controlled, regulated, or constrained.: Multiplying or increasing in number.  In biology, cell proliferation occurs by a process known as cell division.: Someone who gives blood or tissue or an organ to be used in another person.: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.: Used to indicate the absence or lack of something or someone.: Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.: The conversion of a cell from a normal phenotype, which undergoes a limited number of mitotic divisions, into an aberrant phenotype that is immortal and divides indefinitely. Transformed cells no longer retain cell-cycle checkpoints and may ultimately become malignant cancer cells via additional genetic mutations, or damaging environmental events.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uncontrolled","conceptCode":"C48932","definition":"Not controlled, regulated, or constrained.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Proliferation","conceptCode":"C28378","definition":"Multiplying or increasing in number.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Tissue Donor","conceptCode":"C25168","definition":"Someone who gives blood or tissue or an organ to be used in another person.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Cell","conceptCode":"C12508","definition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Malignant","conceptCode":"C14143","definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Transformation","conceptCode":"C17212","definition":"The conversion of a cell from a normal phenotype, which undergoes a limited number of mitotic divisions, into an aberrant phenotype that is immortal and divides indefinitely. Transformed cells no longer retain cell-cycle checkpoints and may ultimately become malignant cancer cells via additional genetic mutations, or damaging environmental events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"292A1420-D666-B90E-E050-BB89AD437CF4","latestVersionIndicator":"Yes","beginDate":"2016-01-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292A1420-D67F-B90E-E050-BB89AD437CF4","beginDate":"2016-01-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Other new malignancy","valueDescription":"Other New Malignant Neoplasm","ValueMeaning":{"publicId":"5096671","version":"1","preferredName":"Other New Malignant Neoplasm","longName":"5096671","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Having no previous example or precedent or parallel; of a kind not seen before.: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"New","conceptCode":"C25586","definition":"Having no previous example or precedent or parallel; of a kind not seen before.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"289C49EF-8E6B-61B7-E050-BB89AD434384","latestVersionIndicator":"Yes","beginDate":"2016-01-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292A1420-D689-B90E-E050-BB89AD437CF4","beginDate":"2016-01-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Non-Hodgkin lymphoma","valueDescription":"Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"2573076","version":"1","preferredName":"Non-Hodgkin Lymphoma","longName":"2573076","preferredDefinition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Hodgkin Lymphoma","conceptCode":"C3211","definition":"Distinct from Hodgkin lymphoma both morphologically and biologically, non-Hodgkin lymphoma (NHL) is characterized by the absence of Reed-Sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. NHL is clinically classified as indolent, aggressive, or having a variable clinical course. NHL can be of B-or T-/NK-cell lineage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA81-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-09","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"PWEST","dateModified":"2014-05-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292A1420-D6A7-B90E-E050-BB89AD437CF4","beginDate":"2016-01-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Basal cell skin malignancy","valueDescription":"Skin Basal Cell Carcinoma","ValueMeaning":{"publicId":"2961462","version":"1","preferredName":"Skin Basal Cell Carcinoma","longName":"2961462","preferredDefinition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like.. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Basal Cell Carcinoma","conceptCode":"C2921","definition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AB07DC-B5C7-F05E-E040-BB89AD43180B","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292A1420-D6B1-B90E-E050-BB89AD437CF4","beginDate":"2009-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Hodgkin lymphoma","valueDescription":"Hodgkin's Lymphoma","ValueMeaning":{"publicId":"2581278","version":"1","preferredName":"Hodgkin's Lymphoma","longName":"2581278","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells.  There are two distinct subtypes: nodular lymphocyte predominant Hodgkin's lymphoma and classical Hodgkin's lymphoma.  Hodgkin's lymphoma has a bimodal age distribution, and involves primarily lymph nodes.  Current therapy for Hodgkin's lymphoma has resulted in an excellent outcome and cure for the majority of patients. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-04-26","modifiedBy":"LEATHERJ","dateModified":"2008-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292A1420-D6BB-B90E-E050-BB89AD437CF4","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Myelodysplasia / myeloproliferative neoplasm (MDS / MPN)","valueDescription":"Myelodysplastic/Myeloproliferative Disease","ValueMeaning":{"publicId":"2590868","version":"1","preferredName":"Myelodysplastic/Myeloproliferative Disease","longName":"2590868","preferredDefinition":"A category of clonal myeloid disorders that have both myelodysplastic and chronic myeloproliferative features at the time of initial presentation.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic/Myeloproliferative Neoplasm","conceptCode":"C27262","definition":"A category of clonal hematopoietic disorders that have both myelodysplastic and myeloproliferative features at the time of initial presentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"284500E6-BC71-45B5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292A1420-D6CF-B90E-E050-BB89AD437CF4","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Other leukemia","valueDescription":"Other Leukemia","ValueMeaning":{"publicId":"2683292","version":"1","preferredName":"Other Leukemia","longName":"2683292","preferredDefinition":"Not otherwise specified.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A947A96-C0A1-73DC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-20","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292A1420-D6D9-B90E-E050-BB89AD437CF4","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Central nervous system (CNS) malignancy (e.g. glioblastoma, astrocytoma)","valueDescription":"Central Nervous System Neoplasm","ValueMeaning":{"publicId":"2593161","version":"1","preferredName":"Central Nervous System Neoplasm","longName":"2593161","preferredDefinition":"Abnormal growth of cells that comprise the tissues of the central nervous system (brain and spinal cord), without designation of benign or malignant nature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System Neoplasm","conceptCode":"C9293","definition":"A benign or malignant, primary or metastatic neoplasm that affects the brain, meninges, or spinal cord.  Representative examples of primary neoplasms include astrocytoma, oligodendroglioma, ependymoma, and meningioma.  Representative examples of metastatic neoplasms include carcinoma and leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6FA9-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"KUMMEROA","dateModified":"2022-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29394FE6-538A-B1AA-E050-BB89AD430159","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-13","modifiedBy":"ONEDATA","dateModified":"2016-01-13","deletedIndicator":"No"},{"value":"Gastrointestinal malignancy (e.g. colon, rectum, stomach, pancreas, intestine)","valueDescription":"Malignant Gastrointestinal Neoplasm","ValueMeaning":{"publicId":"2683288","version":"1","preferredName":"Malignant Gastrointestinal Neoplasm","longName":"2683288","preferredDefinition":"A primary or metastatic malignant neoplasm involving any part of the gastrointestinal system. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Digestive System Neoplasm","conceptCode":"C4890","definition":"A primary or metastatic malignant neoplasm involving any part of the digestive system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A947A96-C015-73DC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-20","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29394FE6-5394-B1AA-E050-BB89AD430159","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-13","modifiedBy":"ONEDATA","dateModified":"2016-01-13","deletedIndicator":"No"},{"value":"Genitourinary malignancy (e.g. kidney, bladder, ovary, testicle, genitalia, uterus, cervix)","valueDescription":"Genitourinary System Malignant Neoplasm","ValueMeaning":{"publicId":"2789878","version":"1","preferredName":"Genitourinary System Malignant Neoplasm","longName":"2789878","preferredDefinition":"The body system that includes all organs involved in reproduction and in the formation and voidance of urine.: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Genitourinary System","conceptCode":"C12810","definition":"The body system that includes all organs involved in reproduction and in the formation and voidance of urine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"580DD4DB-7B83-73C3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-09-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29394FE6-539E-B1AA-E050-BB89AD430159","beginDate":"2008-09-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-13","modifiedBy":"ONEDATA","dateModified":"2016-01-13","deletedIndicator":"No"},{"value":"Oropharyngeal cancer (e.g. tongue, buccal mucosa)","valueDescription":"Oropharyngeal Carcinoma","ValueMeaning":{"publicId":"2683233","version":"1","preferredName":"Oropharyngeal Carcinoma","longName":"2683233","preferredDefinition":"Carcinoma, predominantly squamous cell, arising from epithelial cells of the oropharynx. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oropharyngeal Carcinoma","conceptCode":"C9105","definition":"Carcinoma, predominantly squamous cell, arising from the epithelial cells of the oropharynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A83FCB0-9D0F-2594-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-19","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29394FE6-53A8-B1AA-E050-BB89AD430159","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-13","modifiedBy":"ONEDATA","dateModified":"2016-01-13","deletedIndicator":"No"},{"value":"Lung cancer","valueDescription":"Lung Carcinoma","ValueMeaning":{"publicId":"2581279","version":"1","preferredName":"Lung Carcinoma","longName":"2581279","preferredDefinition":"A carcinoma originating in the lung.  Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas.  Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas.  Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Carcinoma","conceptCode":"C4878","definition":"A carcinoma originating in the lung. Lung carcinomas usually arise from the epithelium that lines the bronchial tree (bronchogenic carcinomas), and are classified as small cell or non-small cell carcinomas. Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas to the lung are also common, and can be difficult to distinguish from primary tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292962AA-513F-C244-E050-BB89AD431D67","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Thyroid cancer","valueDescription":"Thyroid Gland Carcinoma","ValueMeaning":{"publicId":"2581280","version":"1","preferredName":"Thyroid Gland Carcinoma","longName":"2581280","preferredDefinition":"A carcinoma arising from the thyroid gland.  It is usually an adenocarcinoma and includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Carcinoma","conceptCode":"C4815","definition":"A carcinoma arising from the thyroid gland. It includes the following main subtypes: follicular, papillary, medullary, poorly differentiated, and anaplastic carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A8D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292962AA-5149-C244-E050-BB89AD431D67","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Melanoma","valueDescription":"Melanoma","ValueMeaning":{"publicId":"2567413","version":"1","preferredName":"Melanoma","longName":"2567413","preferredDefinition":"A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D462-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292962AA-5153-C244-E050-BB89AD431D67","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Sarcoma","valueDescription":"Sarcoma","ValueMeaning":{"publicId":"2574579","version":"1","preferredName":"Sarcoma","longName":"2574579","preferredDefinition":"A usually aggressive malignant mesenchymal cell tumor most commonly arising from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels.  Sarcomas occur in both children and adults.  The prognosis depends largely on the degree of differentiation (grade) of the tumor.  Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcoma","conceptCode":"C9118","definition":"A usually aggressive malignant neoplasm of the soft tissue or bone. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. Sarcomas occur in both children and adults. The prognosis depends largely on the degree of differentiation (grade) of the neoplasm. Representative subtypes are liposarcoma, leiomyosarcoma, osteosarcoma, and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F060-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-04-26","modifiedBy":"REEVESD","dateModified":"2006-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292962AA-515D-C244-E050-BB89AD431D67","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Acute myeloid leukemia (AML / ANLL)","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2581275","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"2581275","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A88-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-18","modifiedBy":"ONEDATA","dateModified":"2006-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292962AA-5171-C244-E050-BB89AD431D67","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Clonal cytogenetic abnormality without leukemia or MDS","valueDescription":"Cytogenetic Abnormality Without Leukemia Or MDS","ValueMeaning":{"publicId":"3059841","version":"1","preferredName":"Cytogenetic Abnormality Without Leukemia Or MDS","longName":"3059841","preferredDefinition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.: Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004: Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Abnormality","conceptCode":"C2950","definition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"841F9B68-DD6B-1A3C-E040-BB89AD433DF0","latestVersionIndicator":"Yes","beginDate":"2010-04-13","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-04-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"292962AA-51FD-C244-E050-BB89AD431D67","beginDate":"2010-04-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Breast cancer","valueDescription":"Breast Carcinoma","ValueMeaning":{"publicId":"3589907","version":"1","preferredName":"Breast Carcinoma","longName":"3589907","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9FF059F-8BC9-73AE-E040-BB89AD4367D2","latestVersionIndicator":"Yes","beginDate":"2012-09-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-09-18","modifiedBy":"ONEDATA","dateModified":"2012-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292962AA-5207-C244-E050-BB89AD431D67","beginDate":"2007-09-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Myeloproliferative neoplasm (MPN)","valueDescription":"Myeloproliferative Neoplasm","ValueMeaning":{"publicId":"4264963","version":"1","preferredName":"Myeloproliferative Neoplasm","longName":"4264963","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3B48-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292962AA-5211-C244-E050-BB89AD431D67","beginDate":"2015-03-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome (MDS)","valueDescription":"Myelodysplastic Syndrome","ValueMeaning":{"publicId":"3946618","version":"1","preferredName":"Myelodysplastic Syndrome","longName":"3946618","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA87B0E5-6712-6876-E040-BB89AD437204","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-06","modifiedBy":"GDEEN","dateModified":"2022-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292962AA-521B-C244-E050-BB89AD431D67","beginDate":"2015-03-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Squamous cell skin malignancy","valueDescription":"Skin Squamous Cell","ValueMeaning":{"publicId":"4735807","version":"1","preferredName":"Skin Squamous Cell","longName":"4735807","preferredDefinition":"A flat, scale-like epithelial cell found on the outer covering of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Squamous Cell","conceptCode":"C33562","definition":"A flat, scale-like epithelial cell found on the outer covering of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"108FE035-C106-253F-E050-BB89AD437954","latestVersionIndicator":"Yes","beginDate":"2015-03-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"292962AA-5225-C244-E050-BB89AD431D67","beginDate":"2015-03-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"},{"value":"Other malignancy","valueDescription":"Other Malignant Neoplasm","ValueMeaning":{"publicId":"2683293","version":"1","preferredName":"Other Malignant Neoplasm","longName":"2683293","preferredDefinition":"Not otherwise specified.: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A947A96-C0C6-73DC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-20","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A32453B-DBC2-DCD5-E050-BB89AD4355DC","beginDate":"2016-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-08-16","modifiedBy":"ONEDATA","dateModified":"2016-08-16","deletedIndicator":"No"},{"value":"Other skin malignancy (basal cell, squamous)","valueDescription":"Other Malignant Skin Neoplasm","ValueMeaning":{"publicId":"2683290","version":"1","preferredName":"Other Malignant Skin Neoplasm","longName":"2683290","preferredDefinition":"Not otherwise specified.: A primary or metastatic tumor involving the skin.  Primary malignant skin tumors most often are carcinomas (either basal cell or squamous cell carcinomas that arise from cells in the epidermis) or melanomas that arise from pigment-containing skin melanocytes.  Metastatic tumors to the skin include carcinomas and lymphomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Skin Neoplasm","conceptCode":"C2920","definition":"A primary or metastatic malignant neoplasm involving the skin. Primary malignant skin neoplasms most often are carcinomas (either basal cell or squamous cell carcinomas) or melanomas. Metastatic malignant neoplasms to the skin include carcinomas and lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A947A96-C03E-73DC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-20","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A32453B-DBCC-DCD5-E050-BB89AD4355DC","beginDate":"2016-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-08-16","modifiedBy":"ONEDATA","dateModified":"2016-08-16","deletedIndicator":"No"},{"value":"Lymphoma or lymphoproliferative disease","valueDescription":"Lymphoma Or Lymphoproliferative Disorder","ValueMeaning":{"publicId":"2683291","version":"1","preferredName":"Lymphoma Or Lymphoproliferative Disorder","longName":"2683291","preferredDefinition":"A malignant (clonal) proliferation of B- or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites.  This category includes Non-Hodgkin's lymphomas and Hodgkin's lymphomas. -- 2003: Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lymphoproliferative Disorder","conceptCode":"C9308","definition":"A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A947A96-C067-73DC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-20","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3A32453B-DBD6-DCD5-E050-BB89AD4355DC","beginDate":"2016-08-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-08-16","modifiedBy":"ONEDATA","dateModified":"2016-08-16","deletedIndicator":"No"},{"value":"Other solid tumor","valueDescription":"Other Solid Neoplasm","ValueMeaning":{"publicId":"2672902","version":"1","preferredName":"Other Solid Neoplasm","longName":"2672902","preferredDefinition":"Not otherwise specified.: Cancer of body tissues other than blood, bone marrow, or the lymphatic system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37D5FE1C-A576-09FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-16","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CE8D7D0-F532-747E-E053-F662850AFDAA","beginDate":"2018-12-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-12-13","modifiedBy":"ONEDATA","dateModified":"2018-12-13","deletedIndicator":"No"},{"value":"Other hematologic malignancy","valueDescription":"Other Hematologic Malignant Neoplasm","ValueMeaning":{"publicId":"6588342","version":"1","preferredName":"Other Hematologic Malignant Neoplasm","longName":"6588342","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Pertaining to or related to the blood and blood-forming organs.: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CE84286-98BC-59B1-E053-F662850A8374","latestVersionIndicator":"Yes","beginDate":"2018-12-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-12-13","modifiedBy":"ONEDATA","dateModified":"2018-12-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CE84286-98D5-59B1-E053-F662850A8374","beginDate":"2018-12-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-12-13","modifiedBy":"ONEDATA","dateModified":"2018-12-13","deletedIndicator":"No"},{"value":"Multiple myeloma / plasma cell disorder (PCD)","valueDescription":"Plasma Cell Myeloma","ValueMeaning":{"publicId":"5581351","version":"1","preferredName":"Plasma Cell Myeloma","longName":"5581351","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42019733-B9DD-634F-E053-F662850A5A61","latestVersionIndicator":"Yes","beginDate":"2016-11-23","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-11-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CE84286-98E9-59B1-E053-F662850A8374","beginDate":"2018-12-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-12-13","modifiedBy":"ONEDATA","dateModified":"2018-12-13","deletedIndicator":"No"},{"value":"Lymphoma","valueDescription":"Lymphoma","ValueMeaning":{"publicId":"2567355","version":"1","preferredName":"Lymphoma","longName":"2567355","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D428-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-18","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-18","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CE84286-98F3-59B1-E053-F662850A8374","beginDate":"2018-12-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-12-13","modifiedBy":"ONEDATA","dateModified":"2018-12-13","deletedIndicator":"No"},{"value":"Leukemia","valueDescription":"Leukemia","ValueMeaning":{"publicId":"3179697","version":"1","preferredName":"Leukemia","longName":"3179697","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F258D4-9F60-3E56-E040-BB89AD436715","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"SHIDED","dateCreated":"2011-01-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CE84286-98FD-59B1-E053-F662850A8374","beginDate":"2018-12-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-12-13","modifiedBy":"ONEDATA","dateModified":"2018-12-13","deletedIndicator":"No"},{"value":"Other CNS malignancy","valueDescription":"Other Malignant Central Nervous System Neoplasm","ValueMeaning":{"publicId":"7620977","version":"1","preferredName":"Other Malignant Central Nervous System Neoplasm","longName":"7620977","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A primary or metastatic malignant neoplasm involving the brain or spinal cord.  Representative examples include anaplastic astrocytoma, glioblastoma, anaplastic (malignant) meningioma, lymphoma, and metastatic carcinoma from another anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Central Nervous System Neoplasm","conceptCode":"C4627","definition":"A primary or metastatic malignant neoplasm involving the brain or spinal cord.  Representative examples include anaplastic astrocytoma, glioblastoma, anaplastic (malignant) meningioma, lymphoma, and metastatic carcinoma from another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BED7ABC9-0F53-2FAC-E053-4EBD850A1E2D","latestVersionIndicator":"Yes","beginDate":"2021-03-31","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-31","modifiedBy":"ONEDATA","dateModified":"2021-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BED7ABC9-0F6C-2FAC-E053-4EBD850A1E2D","beginDate":"2021-03-31","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-31","modifiedBy":"ONEDATA","dateModified":"2021-03-31","deletedIndicator":"No"},{"value":"Glioma","valueDescription":"Glioma","ValueMeaning":{"publicId":"5043642","version":"1","preferredName":"Glioma","longName":"5043642","preferredDefinition":"A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioma","conceptCode":"C3059","definition":"A benign or malignant brain and spinal cord tumor that arises from glial cells (astrocytes, oligodendrocytes, ependymal cells). Tumors that arise from astrocytes are called astrocytic tumors or astrocytomas. Tumors that arise from oligodendrocytes are called oligodendroglial tumors. Tumors that arise from ependymal cells are called ependymomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2434C622-BEA6-E3B1-E050-BB89AD43792A","latestVersionIndicator":"Yes","beginDate":"2015-11-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BED7ABC9-0F76-2FAC-E053-4EBD850A1E2D","beginDate":"2021-03-31","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-31","modifiedBy":"ONEDATA","dateModified":"2021-03-31","deletedIndicator":"No"},{"value":"Meningioma","valueDescription":"Meningioma","ValueMeaning":{"publicId":"4265263","version":"1","preferredName":"Meningioma","longName":"4265263","preferredDefinition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade I tumors, and some are WHO grade II or III tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningioma","conceptCode":"C3230","definition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F68D1573-4D52-FC76-E040-BB89AD43431A","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BED7ABC9-0F80-2FAC-E053-4EBD850A1E2D","beginDate":"2021-03-31","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-31","modifiedBy":"ONEDATA","dateModified":"2021-03-31","deletedIndicator":"No"},{"value":"Soft tissue sarcoma","valueDescription":"Soft Tissue Sarcoma","ValueMeaning":{"publicId":"3384698","version":"1","preferredName":"Soft Tissue Sarcoma","longName":"3384698","preferredDefinition":"A malignant mesenchymal neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Soft Tissue Sarcoma","conceptCode":"C9306","definition":"A malignant neoplasm arising from muscle tissue, adipose tissue, blood vessels, fibrous tissue, or other supportive tissues excluding the bones.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9A3DDB0-75C8-1600-E040-BB89AD432CFF","latestVersionIndicator":"Yes","beginDate":"2012-02-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEB0BB54-DB8E-13EF-E053-4EBD850A8B07","beginDate":"2021-03-29","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-29","modifiedBy":"ONEDATA","dateModified":"2021-03-29","deletedIndicator":"No"},{"value":"Bone sarcoma","valueDescription":"Bone Sarcoma","ValueMeaning":{"publicId":"2593148","version":"1","preferredName":"Bone Sarcoma","longName":"2593148","preferredDefinition":"A malignant mesenchymal tumor of the bone.  Bone sarcomas can either arise from the bones (primary bone sarcomas) or spread to the bones from other anatomic sites. --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Sarcoma","conceptCode":"C9312","definition":"A sarcoma that arises from the bone.  Representative examples are osteosarcoma and chondrosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286E976F-6E67-3730-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEB0BB54-DB98-13EF-E053-4EBD850A8B07","beginDate":"2021-03-29","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-29","modifiedBy":"ONEDATA","dateModified":"2021-03-29","deletedIndicator":"No"},{"value":"Overlapping myelodysplasia / myeloproliferative neoplasm (MDS / MPN)","valueDescription":"Myelodysplastic Syndrome Myeloproliferative Neoplasm Overlap Syndrome","ValueMeaning":{"publicId":"7619459","version":"1","preferredName":"Myelodysplastic Syndrome Myeloproliferative Neoplasm Overlap Syndrome","longName":"7619459","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001): A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008): An autoimmune, connective tissue disorder in which the patient exhibits features from two or more diseases. These typically include systemic sclerosis, dermatomyositis, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren syndrome; in pediatrics the respective pediatric entities are encountered.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Overlap Syndrome","conceptCode":"C116801","definition":"An autoimmune, connective tissue disorder in which the patient exhibits features from two or more diseases. These typically include systemic sclerosis, dermatomyositis, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren syndrome; in pediatrics the respective pediatric entities are encountered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEB0BB54-DBA6-13EF-E053-4EBD850A8B07","latestVersionIndicator":"Yes","beginDate":"2021-03-29","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-29","modifiedBy":"ONEDATA","dateModified":"2021-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEB0BB54-DBBF-13EF-E053-4EBD850A8B07","beginDate":"2021-03-29","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-29","modifiedBy":"ONEDATA","dateModified":"2021-03-29","deletedIndicator":"No"},{"value":"Acute lymphoblastic leukemia (ALL)","valueDescription":"Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"3322383","version":"1","preferredName":"Acute Lymphoblastic Leukemia","longName":"3322383","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B36DFA8A-BB5D-6AE7-E040-BB89AD432073","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-06","modifiedBy":"ONEDATA","dateModified":"2011-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEB0BB54-DBC9-13EF-E053-4EBD850A8B07","beginDate":"2021-03-29","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-29","modifiedBy":"ONEDATA","dateModified":"2021-03-29","deletedIndicator":"No"},{"value":"Chronic lymphocytic leukemia","valueDescription":"Chronic Lymphocytic Leukemia","ValueMeaning":{"publicId":"4264837","version":"1","preferredName":"Chronic Lymphocytic Leukemia","longName":"4264837","preferredDefinition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FFD5-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB5D3564-91BA-1B24-E053-4EBD850ADE95","beginDate":"2022-03-29","endDate":null,"createdBy":"MALUMK","dateCreated":"2022-03-29","modifiedBy":"ONEDATA","dateModified":"2022-03-29","deletedIndicator":"No"},{"value":"Chronic myeloid leukemia","valueDescription":"CML","ValueMeaning":{"publicId":"2837953","version":"1","preferredName":"CML","longName":"2837953","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6282862D-CE51-EC8D-E040-BB89AD434A77","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DB5D3564-91CE-1B24-E053-4EBD850ADE95","beginDate":"2022-03-29","endDate":null,"createdBy":"MALUMK","dateCreated":"2022-03-29","modifiedBy":"ONEDATA","dateModified":"2022-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2684692","version":"1","preferredName":"Malignant Neoplasm Type","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004:Type; a subdivision of a particular kind of thing.","longName":"C9305:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AFC11F7-407B-1DA1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-25","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-09-25","modifiedBy":"ONEDATA","dateModified":"2007-09-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"292962AA-510A-C244-E050-BB89AD431D67","latestVersionIndicator":"Yes","beginDate":"2016-01-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-01-12","modifiedBy":"MALUMK","dateModified":"2022-03-29","changeDescription":". Added 3 PVs that were missing from previous version needed for 2400r5. AK 8/16/16 Added PVs for 2400. AK 12/13/18. PVs added for 2100r7. 03/29/2021 KMM. PVs added for 2100r7. 03/31/2021 KMM. PVs added for 4000r9. 03/29/2022 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"3160397","version":"1","longName":"2455: Selective Post-Transplant Essential Data","context":"NHLBI"},{"publicId":"2964925","version":"1","longName":"2450r1: Post-TED","context":"NHLBI"},{"publicId":"2964902","version":"1","longName":"2100r1: 100 Days Post-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"HPST_NMM_new_malig_type","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"post_ted_new_malig_spec","type":"NMDP_FN","context":"NHLBI"},{"name":"TPST_NMM_new_malig_type","type":"NMDP_FN","context":"NHLBI"},{"name":"CPST_NMM_new_malig_type","type":"NMDP_FN","context":"NHLBI"},{"name":"NM_NMLM_new_malig_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the new malignant ne","type":"Preferred Question Text","description":"What was the new malignant neoplasm, lymphoproliferative or myelodysplastic / myeloproliferative disorder?","url":null,"context":"NHLBI"},{"name":"Specify:","type":"Alternate Question Text","description":"Specify:","url":null,"context":"NHLBI"},{"name":"Specify which new disease(s) occurred","type":"Alternate Question Text","description":"Specify which new disease(s) occurred:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2677021","type":"BRIDG Mapping Path","description":"\"[IF EXISTS THEN \"\"true\"\" ELSE \"\"false\"\"] PerformedProcedure [post-HCT follow-up monitoring] > DefinedProcedure [post-HCT follow-up monitoring] > DefinedCompositionRelationship > DefinedObservation [diagnose disease] PerformedObservation [diagnose disease] > PerformedDiagnosis.value(ANY=>CD) = {specified new disorder}\"","url":null,"context":"NHLBI"},{"name":"Specify the new malignancy","type":"Application Standard Question Text","description":"Specify the new malignancy","url":null,"context":"NHLBI"},{"name":"Specify the new malignancy","type":"Alternate Question Text","description":"Specify the new malignancy","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1C7D36EC-7AC6-BD03-E050-BB89AD43098D","latestVersionIndicator":"Yes","beginDate":"2015-08-04","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-08-04","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}